EGFR and neoplasm: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has a good effect as a treatment for NSCLC cases with activated EGFR mutations.[2,3] Compared with standard chemotherapy, upfront TKI has a better progression-free survival in patients with EGFR mutations.[4–6] However, a lack of sufficient tumor tissue has an impact on genetic testing in clinical practice.